Provide feedbackProvide feedback

Home :: Internal Medicine

CSL Behring starts Phase I/II trial of treatment candidate for hereditary angioedema

Thursday, May 03 2012 | Comments
Evidence Grade 0 What's This?

CSL Behring began a Phase I/II study to investigate a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in adults with hereditary angioedema (HAE) type I or type II. The open-label trial is being conducted as part of the COMPACT program, which is assessing optimal management in preventing angioedema with low-volume, subcutaneous C1-INH replacement therapy. After an initial IV injection of C1-INH, each of the trial participants will be assigned to...

CSL Behring began a Phase I/II study to investigate a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in adults with hereditary angioedema (HAE) type I or type II.

The open-label trial is being conducted as part of the COMPACT program, which is assessing optimal management in preventing angioedema with low-volume, subcutaneous C1-INH replacement therapy.

After an initial IV injection of C1-INH, each of the trial participants will be assigned to receive a single subcutaneous injection of the volume-reduced formulation of C1-INH twice weekly for four weeks. The study subjects will participate in two of these treatment periods with two different doses of volume-reduced C1-INH.

During the trial, researchers will monitor C1-INH levels in the blood and will evaluate the drug's safety and tolerability at different doses.

Latest News

MannKind, Tolero sign drug development agreement potentially worth $130 million Verusmed

Monday, April 30 2012 | Comments
Evidence Grade 0 What's This?

MannKind Corp. and Tolero Pharmaceuticals Inc. established a collaboration and license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's Bruton's tyrosine kinase (Btk) inhibitor program for hematologic malignancies and inflammatory diseases.

The agreement calls...



Amylin finishes BLA submission for metreleptin as treatment for conditions associated with rare forms of lipodystrophy Verusmed

Tuesday, April 03 2012 | Comments
Evidence Grade 0 What's This?

Amylin Pharmaceuticals Inc. completed its Biologics License Application (BLA) submission to the Food and Drug Administration for the use of metreleptin to treat diabetes and/or hypertriglyceridemia in pediatric and adult patients with rare forms of lipodystrophy.

As previously reported, Amylin initiated the rolling BLA submission in December 2010 with...



La Jolla acquires rights to anticancer/antifibrotic agent, appoints new CEO Verusmed

Monday, January 30 2012 | Comments
Evidence Grade 0 What's This?

La Jolla Pharmaceutical Co. gained the global development and commercialization rights to GCS-100 from Solana Therapeutics Inc.

GCS-100 is a first-in-class inhibitor of galectin-3, a molecular target implicated in cancer and chronic organ failure. La Jolla explained that inhibitors of galectin-3 are "attractive" therapeutic candidates for a variety of diseases, including cancer, heart failure, kidney disease, pulmonary...



AstraZeneca's Atacand associated with lower risk of all-cause mortality in patients with HF versus losartan, data suggest Verusmed

Monday, December 19 2011 | Comments
Evidence Grade 0 What's This?

Individuals with heart failure who are treated with AstraZeneca Pharmaceuticals LP's Atacand (candesartan cilexetil), an angiotensin II receptor blocker (ARB), have a lower risk of all-cause mortality than do those treated with the ARB losartan potassium, according to an analysis of data from an unselected population of patients with heart failure.

The analysis was based on data from the Swedish Heart Failure Registry and included...





  1. No articles have been read
  1. No articles have been emailed
Videos